Cellular and molecular mechanisms of metformin: An overview

Clinical Science

Volumn 122, Issue 6, 2012, Pages 253-270

  Viollet, Benoit ^a,b,c   Guigas, Bruno ^d   Sanz Garcia, Nieves ^a,b,c   Leclerc, Jocelyne ^a,b,c   Foretz, Marc ^a,b,c   Andreelli, Fabrizio ^a,b,c,e  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

AMP activated protein kinase (AMPK); Cancer; Cardiovascular system; Metabolism; Metformin; Mitochondrion; Type 2 diabetes

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; CYTOCHROME P450; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; FOLLITROPIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; METFORMIN; NITRIC OXIDE SYNTHASE; ORGANIC CATION TRANSPORTER 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE LKB1; STEROIDOGENIC ACUTE REGULATORY PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; SULFONYLUREA; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANTIDIABETIC AGENT;

ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CIRCADIAN RHYTHM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; FATTY LIVER; GENETIC VARIABILITY; GLUCONEOGENESIS; GLUCOSE METABOLISM; HEART MUSCLE CELL; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPOTOXICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PHARMACOGENETICS; PHARMACOLOGICAL BLOCKING; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; ANIMAL; DRUG EFFECT; FEMALE;

ANIMALS; CARDIOVASCULAR SYSTEM; CIRCADIAN CLOCKS; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; POLYCYSTIC OVARY SYNDROME;

EID: 84855603512     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110386     Document Type: Review

References (162)

1. Adler, A. I., Shaw, E. J., Stokes, T. and Ruiz, F. (2009) Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ 338, b1668.
2. Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R. and Zinman, B. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193-203.
3. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) (1998) Lancet 352, 854-865
4. Selvin, E., Bolen, S., Yeh, H. C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B. and Brancati, F. L. (2008) Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch. Intern. Med. 168, 2070-2080.
5. Lamanna, C., Monami, M., Marchionni, N. and Mannucci, E. (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 13, 221-228.
6. Gunton, J. E., Delhanty, P. J., Takahashi, S. and Baxter, R. C. (2003) Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J. Clin. Endocrinol. Metab. 88, 1323-1332.
7. Maida, A., Lamont, B. J., Cao, X. and Drucker, D. J. (2011) Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 54, 339-349.
8. Cusi, K., Consoli, A. and DeFronzo, R. A. (1996) Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81, 4059-4067.
9. Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V., Chandramouli, V., Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R. and Shulman, G. I. (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49, 2063-2069.
10. Natali, A. and Ferrannini, E. (2006) Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49, 434-441.
11. Argaud, D., Roth, H., Wiernsperger, N. and Leverve, X. M. (1993) Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur. J. Biochem. 213, 1341-1348.
12. Large, V. and Beylot, M. (1999) Modifications of citric acid cycle activity and gluconeogenesis in streptozotocininduced diabetes and effects of metformin. Diabetes 48, 1251-1257.
13. Mithieux, G., Guignot, L., Bordet, J. C. andWiernsperger, N. (2002) Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 51, 139-143.
14. Radziuk, J., Zhang, Z., Wiernsperger, N. and Pye, S. (1997) Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 46, 1406-1413.
15. Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G. et al. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431.
16. Wilcock, C. and Bailey, C. J. (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24, 49-57.
17. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N. et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174.
18. Viollet, B., Guigas, B., Leclerc, J., Hebrard, S., Lantier, L., Mounier, R., Andreelli, F. and Foretz, M. (2009) AMPactivated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. 196, 81-98.
19. Oakhill, J. S., Steel, R., Chen, Z. P., Scott, J. W., Ling, N., Tam, S. and Kemp, B. E. (2011) AMPK is a direct adenylate charge-regulated protein kinase. Science 332, 1433-1435.
20. Xiao, B., Sanders, M. J., Underwood, E., Heath, R., Mayer, F. V., Carmena, D., Jing, C., Walker, P. A., Eccleston, J. F., Haire, L. F. et al. (2011) Structure of mammalian AMPK and its regulation by ADP. Nature 472, 230-233.
21. Hardie, D. G. (2006) Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology 131, 973.
22. El-Mir, M. Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M. and Leverve, X. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223-228.
23. Owen, M. R., Doran, E. and Halestrap, A. P. (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607-614.
24. Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhausl, W. and Furnsinn, C. (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53, 1052-1059.
25. Detaille, D., Guigas, B., Chauvin, C., Batandier, C., Fontaine, E., Wiernsperger, N. and Leverve, X. (2005) Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54, 2179-2187.
26. Hinke, S. A., Martens, G. A., Cai, Y., Finsi, J., Heimberg, H., Pipeleers, D. and Van de Casteele, M. (2007) Methyl succinate antagonises biguanide-induced AMPKactivation and death of pancreatic β-cells through restoration of mitochondrial electron transfer. Br. J. Pharmacol. 150, 1031-1043.
27. El-Mir, M. Y., Detaille, D., R-Villanueva G., Delgado-Esteban, M., Guigas, B., Attia, S., Fontaine, E., Almeida, A. and Leverve, X. (2008) Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J. Mol. Neurosci. 34, 77-87.
28. Stephenne, X., Foretz, M., Taleux, N., van der Zon, G., Sokal, E., Hue, L., Viollet, B. and Guigas, B. (2011) Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia, doi: 10.1007/s00125-011-2311-5.
29. Detaille, D., Guigas, B., Leverve, X., Wiernsperger, N. and Devos, P. (2002) Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function. Biochem. Pharmacol. 63, 1259-1272.
30. Guigas, B., Detaille, D., Chauvin, C., Batandier, C., De Oliveira, F., Fontaine, E. and Leverve, X. (2004) Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem. J. 382, 877-884.
31. Schafer, H. J., Mainka, L., Rathgeber, G. and Zimmer, G. (1983) Photoaffinity cross-linking of oligomycin-sensitive ATPase from beef heart mitochondria by 3′-arylazido-8-azido ATP. Biochem. Biophys. Res. Commun. 111, 732-739.
32. Batandier, C., Guigas, B., Detaille, D., El-Mir, M. Y., Fontaine, E., Rigoulet, M. and Leverve, X. M. (2006) The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J. Bioenerg. Biomembr. 38, 33-42.
33. 2 emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radical Biol. Med. 49, 1082-1087.
34. Freisleben, H. J., Ruckert, S.,Wiernsperger, N. and Zimmer, G. (1992) The effects of glucose, insulin and metformin on the order parameters of isolated red cell membranes. An electron paramagnetic resonance spectroscopic study. Biochem. Pharmacol. 43, 1185-1194.
35. Muller, S., Denet, S., Candiloros, H., Barrois, R., Wiernsperger, N., Donner, M. and Drouin, P. (1997) Action of metformin on erythrocyte membrane fluidity in vitro and in vivo. Eur. J. Pharmacol. 337, 103-110.
36. Hawley, S. A., Ross, F. A., Chevtzoff, C., Green, K. A., Evans, A., Fogarty, S., Towler, M. C., Brown, L. J., Ogunbayo, O. A., Evans, A. M. and Hardie, D. G. (2010) Use of cells expressing γ subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11, 554-565.
37. Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M. and Cantley, L. C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646.
38. Koo, S. H., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P. et al. (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109-1111.
39. Dentin, R., Hedrick, S., Xie, J., Yates, III, J. and Montminy, M. (2008) Hepatic glucose sensing via the CREB coactivator CRTC2. Science 319, 1402-1405.
40. Caton, P. W., Nayuni, N. K., Kieswich, J., Khan, N. Q., Yaqoob, M. M. and Corder, R. (2010) Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J. Endocrinol. 205, 97-106.
41. Liu, Y., Dentin, R., Chen, D., Hedrick, S., Ravnskjaer, K., Schenk, S., Milne, J., Meyers, D. J., Cole, P., Yates, III, J. et al. (2008) A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456, 269-273.
42. He, L., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., Radovick, S. and Wondisford, F. E. (2009) Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635-646.
43. Kim, Y. D., Park, K. G., Lee, Y. S., Park, Y. Y., Kim, D. K., Nedumaran, B., Jang, W. G., Cho, W. J., Ha, J., Lee, I. K. et al. (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57, 306-314.
44. Lee, J. M., Seo, W. Y., Song, K. H., Chanda, D., Kim, Y. D., Kim, D. K., Lee, M. W., Ryu, D., Kim, Y. H., Noh, J. R. et al. (2010) AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner. J. Biol. Chem. 285, 32182-32191.
45. Takashima, M., Ogawa, W., Hayashi, K., Inoue, H., Kinoshita, S., Okamoto, Y., Sakaue, H., Wataoka, Y., Emi, A., Senga, Y. et al. (2010) Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. Diabetes 59, 1608-1615.
46. Foretz, M., Hebrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F. and Viollet, B. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355-2369.
47. Miller, R. A. and Birnbaum, M. J. (2010) An energetic tale of AMPK-independent effects of metformin. J. Clin. Invest. 120, 2267-2270.
48. Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler, A., Gagne, G., Iyengar, R. et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403-416.
49. Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G. and Diehl, A. M. (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6, 998-1003.
50. Raso, G. M., Esposito, E., Iacono, A., Pacilio, M., Cuzzocrea, S., Canani, R. B., Calignano, A. and Meli, R. (2009) Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. Eur. J. Pharmacol. 604, 125-131.
51. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Zoli, M. and Melchionda, N. (2001) Metformin in non-alcoholic steatohepatitis. Lancet 358, 893-894.
52. Nair, S., Diehl, A. M., Wiseman, M., Farr, Jr, G. H. and Perrillo, R. P. (2004) Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther. 20, 23-28.
53. Zang, M., Zuccollo, A., Hou, X., Nagata, D., Walsh, K., Herscovitz, H., Brecher, P., Ruderman, N. B. and Cohen, R. A. (2004) AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279, 47898-47905.
54. Foretz, M., Ancellin, N., Andreelli, F., Saintillan, Y., Grondin, P., Kahn, A., Thorens, B., Vaulont, S. and Viollet, B. (2005) Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54, 1331-1339.
55. Foretz, M., Carling, D., Guichard, C., Ferre, P. and Foufelle, F. (1998) AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J. Biol. Chem. 273, 14767-14771.
56. Hong, Y. H., Varanasi, U. S., Yang, W. and Leff, T. (2003) AMP-activated protein kinase regulates HNF4α transcriptional activity by inhibiting dimer formation and decreasing protein stability. J. Biol. Chem. 278, 27495-27501.
57. Kawaguchi, T., Osatomi, K., Yamashita, H., Kabashima, T. and Uyeda, K. (2002) Mechanism for fatty acid 'sparing' effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J. Biol. Chem. 277, 3829-3835.
58. Leclerc, I., Lenzner, C., Gourdon, L., Vaulont, S., Kahn, A. and Viollet, B. (2001) Hepatocyte nuclear factor-4α involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes 50, 1515-1521.
59. Yang, W., Hong, Y. H., Shen, X. Q., Frankowski, C., Camp, H. S. and Leff, T. (2001) Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J. Biol. Chem. 276, 38341-38344.
60. Li, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, E., Shyy, J. Y. et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13, 376-388.
61. Kim, E., Liu, N. C., Yu, I. C., Lin, H. Y., Lee, Y. F., Sparks, J. D., Chen, L. M. and Chang, C. (2011) Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes 60, 1493-1503.
62. Takiyama, Y., Harumi, T., Watanabe, J., Fujita, Y., Honjo, J., Shimizu, N., Makino, Y. and Haneda, M. (2011) Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes 60, 981-992.
63. Morales, A. I., Detaille, D., Prieto, M., Puente, A., Briones, E., Arevalo, M., Leverve, X., Lopez-Novoa, J. M. and El-Mir, M. Y. (2010) Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int. 77, 861-869.
64. Cufi, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J. and Menendez, J. A. (2010) Metformin against TGFβ-induced epithelial-tomesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 9, 4461-4468.
65. Piwkowska, A., Rogacka, D., Jankowski, M., Dominiczak, M. H., Stepinski, J. K. and Angielski, S. (2010) Metformin induces suppression of NAD(P)H oxidase activity in podocytes. Biochem. Biophys. Res. Commun. 393, 268-273.
66. Louro, T. M., Matafome, P. N., Nunes, E. C., da Cunha, F. X. and Seica, R. M. (2011) Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. Eur. J. Pharmacol. 653, 89-94.
67. Wang, W., Guo, X. H., Wu, H. H., Wang, N. H. and Xu, X. S. (2006) Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney. Beijing Da Xue Xue Bao 38, 170-175.
68. Takiar, V., Nishio, S., Seo-Mayer, P., King, Jr, J. D., Li, H., Zhang, L., Karihaloo, A., Hallows, K. R., Somlo, S. and Caplan, M. J. (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl. Acad. Sci. U.S.A. 108, 2462-2467.
69. Pilmore, H. L. (2010) Review: metformin: potential benefits and use in chronic kidney disease. Nephrology 15, 412-418.
70. Nye, H. J. and Herrington, W. G. (2011) Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin. Pract. 118, c380-c383.
71. Frid, A., Sterner, G. N., Londahl, M., Wiklander, C., Cato, A., Vinge, E. and Andersson, A. (2010) Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care 33, 1291-1293.
72. Hurst, R. T. and Lee, R. W. (2003) Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann. Intern. Med. 139, 824-834.
73. Johnson, J. A., Simpson, S. H., Toth, E. L. and Majumdar, S. R. (2005) Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabetic Med. 22, 497-502.
74. Johnson, J. A., Majumdar, S. R., Simpson, S. H. and Toth, E. L. (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25, 2244-2248.
75. Yin, M., van der Horst, I. C., van Melle, J. P., Qian, C., van Gilst, W. H., Sillje, H. H. and de Boer, R. A. (2011) Metformin improves cardiac function in a non-diabetic rat model of post-MI heart failure. Am. J. Physiol. Heart Circ. Physiol. 301, H459-H468.
76. Kravchuk, E., Grineva, E., Bairamov, A., Galagudza, M. and Vlasov, T. (2011) The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus Type II. Exp. Diabetes Res. 2011, 907496.
77. Yeh,C.H., Chen, T. P., Wang, Y.C., Lin, Y. M. and Fang, S.W. (2010) AMP-activated protein kinase activation during cardioplegia-induced hypoxia/reoxygenation injury attenuates cardiomyocytic apoptosis via reduction of endoplasmic reticulum stress. Mediators Inflamm. 2010, 130636.
78. Scolletta, S. and Biagioli, B. (2010) Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Biomed. Pharmacother. 64, 203-207.
79. Lopaschuk, G. D. (2006) Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin. Cardiothorac. Vasc. Anesth. 10, 228-230.
80. Benes, J., Kazdova, L., Drahota, Z., Houstek, J., Medrikova, D., Kopecky, J., Kovarova, N., Vrbacky, M., Sedmera, D., Strnad, H. et al. (2011) Effect of metformin therapy on cardiac function and survival in a volumeoverload model of heart failure in rats. Clin. Sci. 121, 29-41.
81. Khurana, R. and Malik, I. S. (2010) Metformin: safety in cardiac patients. Heart 96, 99-102.
82. MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S., Jhund, P. S., Petrie, M. C., McMurray, J. J., Petrie, J. R. and McAlister, F. A. (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 33, 1213-1218.
83. Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T. and Johnson, J. A. (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28, 2345-2351.
84. Eurich, D. T. and McAlister, F. A. (2011)Wrongfully accused: metformin use in heart failure. Expert Rev. Cardiovasc. Ther. 9, 147-150.
85. Roussel, R., Travert, F., Pasquet, B.,Wilson, P.W., Smith, Jr, S. C., Goto, S., Ravaud, P., Marre, M., Porath, A., Bhatt, D. L. and Steg, P. G. (2010) Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med. 170, 1892-1899.
86. Pantalone, K. M., Kattan, M.W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A. and Zimmerman, R. S. (2010) The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 33, 1224-1229.
87. Xie, Z., Lau, K., Eby, B., Lozano, P., He, C., Pennington, B., Li, H., Rathi, S., Dong, Y., Tian, R., Kem, D. and Zou, M. H. (2011) Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60, 1770-1778.
88. Gundewar, S., Calvert, J. W., Jha, S., Toedt-Pingel, I., Ji, S. Y., Nunez, D., Ramachandran, A., Anaya-Cisneros, M., Tian, R. and Lefer, D. J. (2009) Activation of AMPactivated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 104, 403-411.
89. Sasaki, H., Asanuma, H., Fujita, M., Takahama, H., Wakeno, M., Ito, S., Ogai, A., Asakura, M., Kim, J., Minamino, T. et al. (2009) Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 119, 2568-2577.
90. Zhang, C. X., Pan, S. N., Meng, R. S., Peng, C. Q., Xiong, Z. J., Chen, B. L., Chen, G. Q., Yao, F. J., Chen, Y. L., Ma, Y. D. and Dong, Y. G. (2011) Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats. Clin. Exp. Pharmacol. Physiol. 38, 55-62.
91. Muller, G. and Morawietz, H. (2009) Nitric oxide, NAD(P)H oxidase and atherosclerosis. Antioxid. Redox Signaling 11, 1711-1731.
92. Schulz, E., Anter, E., Zou, M. H. and Keaney, Jr, J. F. (2005) Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation 111, 3473-3480.
93. Ouslimani, N., Peynet, J., Bonnefont-Rousselot, D., Therond, P., Legrand, A. and Beaudeux, J. L. (2005) Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metab. Clin. Exp. 54, 829-834.
94. Kukidome, D., Nishikawa, T., Sonoda, K., Imoto, K., Fujisawa, K., Yano, M., Motoshima, H., Taguchi, T., Matsumura, T. and Araki, E. (2006) Activation of AMPactivated protein kinase reduces hyperglycemiainduced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55, 120-127.
95. Rahbar, S., Natarajan, R., Yerneni, K., Scott, S., Gonzales, N. and Nadler, J. L. (2000) Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta 301, 65-77.
96. De Jager, J., Kooy, A., Lehert, P., Bets, D., Wulffele, M. G., Teerlink, T., Scheffer, P. G., Schalkwijk, C. G., Donker, A. J. and Stehouwer, C. D. (2005) Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 257, 100-109.
97. Zou, M. H. and Wu, Y. (2008) AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin. Exp. Pharmacol. Physiol. 35, 535-545.
98. Tang, T., Lord, J. M., Norman, R. J., Yasmin, E. and Balen, A. H. (2010) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev., Art. No.: CD003053, doi: 10.1002/14651858.CD003053.pub4.
99. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2008) Consensus on infertility treatment related to polycystic ovary syndrome. Hum. Reprod. 23, 462-477.
100. Palomba, S., Falbo, A., Zullo, F. and Orio, Jr, F (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30, 1-50.
101. Tosca, L., Solnais, P., Ferre, P., Foufelle, F. and Dupont, J. (2006) Metformin-induced stimulation of adenosine 5′ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol. Reprod. 75, 342-351.
102. Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A. et al. (2008) Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J. Clin. Endocrinol. Metab. 93, 792-800.
103. Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G. and Yee, D. (2010) Diabetes and cancer: a consensus report. Diabetes Care 33, 1674-1685.
104. Jalving, M., Gietema, J. A., Lefrandt, J. D., de Jong, S., Reyners, A. K., Gans, R. O. and de Vries, E. G. (2010) Metformin: taking away the candy for cancer? Eur. J. Cancer 46, 2369-2380.
105. Currie, C. J., Poole, C. D. and Gale, E. A. (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766-1777.
106. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. and Morris, A. D. (2005) Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 330, 1304-1305.
107. Bowker, S. L., Yasui, Y., Veugelers, P. and Johnson, J. A. (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53, 1631-1637.
108. Landman, G.W., Kleefstra, N., van Hateren, K. J., Groenier, K. H., Gans, R. O. and Bilo, H. J. (2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33, 322-326.
109. Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D. and Evans, J. M. (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32, 1620-1625.
110. Bodmer, M., Meier, C., Krahenbuhl, S., Jick, S. S. and Meier, C. R. (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33, 1304-1308.
111. Li, D., Yeung, S. C., Hassan, M. M., Konopleva, M. and Abbruzzese, J. L. (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137, 482-488.
112. Wright, J. L. and Stanford, J. L. (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20, 1617-1622.
113. Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J. F. and Bost, F. (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther. 9, 1092-1099.
114. Goodwin, P. J., Pritchard, K. I., Ennis, M., Clemons, M., Graham, M. and Fantus, I. G. (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 8, 501-505.
115. Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X. Z., Adrian, T. E. and Pour, P. M. (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120, 1263-1270.
116. Algire, C., Amrein, L., Bazile, M., David, S., Zakikhani, M. and Pollak, M. (2010) Diet and tumor LKB1 expression interact to determine sensitivity to antineoplastic effects of metformin in vivo. Oncogene 30, 1174-1182.
117. Kalaany, N. Y. and Sabatini, D. M. (2009) Tumours with PI3K activation are resistant to dietary restriction. Nature 458, 725-731.
118. Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M. et al. (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol. 40, 685-693.
119. Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., McBurnie, W., Fleming, S. and Alessi, D. R. (2008) Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412, 211-221.
120. Min/+ mice. Cancer Sci. 99, 2136-2141.
121. Dowling, R. J., Zakikhani, M., Fantus, I. G., Pollak, M. and Sonenberg, N. (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67, 10804-10812.
122. Gotlieb, W. H., Saumet, J., Beauchamp, M. C., Gu, J., Lau, S., Pollak, M. N. and Bruchim, I. (2008) In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol. 110, 246-250.
123. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. and Pollak, M. (2006) Metformin is an AMP kinasedependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273.
124. Green, A. S., Chapuis, N., Trovati Maciel, T.,Willems, L., Lambert, M., Arnoult, C., Boyer, O., Bardet, V., Park, S., Foretz, M. et al. (2010) The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 116, 4262-4273.
125. Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brule, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J. et al. (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11, 390-401.
126. He, G., Sung, Y. M., Digiovanni, J. and Fischer, S. M. (2006) Thiazolidinediones inhibit insulin-like growth factor-I-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res. 66, 1873-1878.
127. Kisfalvi, K., Eibl, G., Sinnett-Smith, J. and Rozengurt, E. (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 69, 6539-6545.
128. Xiang, X., Saha, A. K., Wen, R., Ruderman, N. B. and Luo, Z. (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun. 321, 161-167.
129. Grisouard, J., Dembinski, K., Mayer, D., Keller, U., Muller, B. and Christ-Crain, M. (2011) Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation. Diabetol. Metab. Syndr. 3, 16.
130. Salminen, A., Hyttinen, J. M. and Kaarniranta, K. (2011) AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. 89, 667-676.
131. Xavier, D. O., Amaral, L. S., Gomes, M. A., Rocha, M. A., Campos, P. R., Cota, B. D., Tafuri, L. S., Paiva, A. M., Silva, J. H., Andrade, S. P. and Belo, A. V. (2010) Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed. Pharmacothe.r 64, 220-225.
132. Ersoy, C., Kiyici, S., Budak, F., Oral, B., Guclu, M., Duran, C., Selimoglu, H., Erturk, E., Tuncel, E. and Imamoglu, S. (2008) The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract. 81, 56-60.
133. Vazquez-Martin, A., Oliveras-Ferraros, C. and Menendez, J. A. (2009) The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8, 88-96.
134. Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y. and Bost, F. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576-3586.
135. Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J. F., Giorgetti-Peraldi, S. and Bost, F. (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366-4372.
136. Zhuang, Y. and Miskimins, W. K. (2008) Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1 and requires p27Kip1 or p21Cip1. J. Mol. Signaling 3, 18.
137. Isakovic, A., Harhaji, L., Stevanovic, D., Markovic, Z., Sumarac-Dumanovic, M., Starcevic, V., Micic, D. and Trajkovic, V. (2007) Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell. Mol. Life Sci. 64, 1290-1302.
138. Liu, B., Fan, Z., Edgerton, S. M., Deng, X. S., Alimova, I. N., Lind, S. E. and Thor, A. D. (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8, 2031-2040.
139. Zhuang, Y. and Miskimins, W. K. (2011) Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol. Cancer Res. 9, 603-615.
140. Ben Sahra, I., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G., Gounon, P., Le Marchand-Brustel, Y., Giorgetti-Peraldi, S., Cormont, M., Bertolotto, C. et al. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70, 2465-2475.
141. Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J. and Thompson, C. B. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293.
142. Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B. and Thompson, C. B. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752.
143. Metzger, B. E., Lowe, L. P., Dyer, A. R., Trimble, E. R., Chaovarindr, U., Coustan, D. R., Hadden, D. R., McCance, D. R., Hod, M., McIntyre, H. D. et al. (2008) Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 358, 1991-2002.
144. Balani, J., Hyer, S. L., Rodin, D. A. and Shehata, H. (2009) Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. Diabetic Med. 26, 798-802.
145. Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R. and Moore, M. P. (2008) Metformin versus insulin for the treatment of gestational diabetes. N. Engl. J. Med. 358, 2003-2015.
146. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A. and Nathan, D. M. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403.
147. Asher, G. and Schibler, U. (2011) Crosstalk between components of circadian and metabolic cycles in mammals. Cell Metab. 13, 125-137.
148. Um, J. H., Yang, S., Yamazaki, S., Kang, H., Viollet, B., Foretz, M. and Chung, J. H. (2007) Activation of 5′-AMP-activated kinase with diabetes drug metformin induces casein kinase Iε (CKIε)-dependent degradation of clock protein mPer2. J. Biol. Chem. 282, 20794-20798.
149. Guigas, B. and Hue, L. (2008) Metformin and the AMP-activated protein kinase. In Metformin: Mechanistic Insights Towards New Applications. (Mithieux, G. and Wiernsperger, N., eds), pp. 81-110, Transworld Research Network, Trivandrum.
150. Kimura, N., Masuda, S., Tanihara, Y., Ueo, H., Okuda, M., Katsura, T. and Inui, K. (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet. 20, 379-386.
151. Umehara, K. I., Iwatsubo, T., Noguchi, K. and Kamimura, H. (2007) Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 37, 818-831.
152. Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M. et al. (2011) Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50, 81-98.
153. Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N. and Pearson, E. R. (2009) Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58, 1434-1439.
154. Tzvetkov, M. V., Vormfelde, S. V., Balen, D., Meineke, I., Schmidt, T., Sehrt, D., Sabolic, I., Koepsell, H. and Brockmoller, J. (2009) The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2 and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86, 299-306.
155. Wang, Z. J., Yin, O. Q., Tomlinson, B. and Chow, M. S. (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics 18, 637-645.
156. Distefano, J. K. and Watanabe, R. M. (2010) Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals 3, 2610-2646.
157. Zhou, K., Bellenguez, C., Spencer, C. C., Bennett, A. J., Coleman, R. L., Tavendale, R., Hawley, S. A., Donnelly, L. A., Schofield, C., Groves, C. J. et al. (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43, 117-120.
158. Algire, C., Zakikhani, M., Blouin, M. J., Shuai, J. H. and Pollak, M. (2008) Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr. Relat. Cancer 15, 833-839.
159. Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. and Struhl, K. (2009) Metformin selectively targets cancer stem cells and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507-7511.
160. Bojkova, B., Orendas, P., Garajova, M., Kassayova, M., Kutna, V., Ahlersova, E. and Ahlers, I. (2009) Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 56, 269-274.
161. Memmott, R. M., Mercado, J. R., Maier, C. R., Kawabata, S., Fox, S. D. and Dennis, P. A. (2010) Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. 3, 1066-1076.
162. Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., Nozaki, Y., Yoneda, K., Fujita, K., Yoneda, M. et al. (2010) Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol. Carcinog. 49, 662-671.